Adrija Hajra, Internal Medicine Physician, currently affiliated with Montefiore Medical Center/Albert Einstein College of Medicine, shared her views with Pharma Focus Asia on “Recent Advances and Future Prospects of Treatment of Pulmonary Hypertension”.
Pulmonary hypertension is defined as increase in pressure of the blood vessels of the lungs. The mechanism of developing pulmonary hypertension is complex. Recently it has been noted that COVID-19-affected patients are at risk of having pulmonary hypertension. There are already multiple available treatments for this condition. In addition, recent advancements are going on in the treatment of pulmonary hypertension.
Currently, there are several therapeutic options available. But there are drugs under trial, and they are presently being evaluated for PHTN treatment. In addition, the recent coronavirus infection 2019 (COVID-19) pandemic has initiated a new interest in PHTN management among health care providers. COVID-19infection has been shown to worsen pre-existing PHTN. COVID-19 is also anticipated to be a significant etiology of PHTN in the coming years due to the long-term sequala of lung fibrosis associated with the infection.
For More Info Visit: https://www.pharmafocusasia.com/manufacturing/prospects-treatment-pulmonary-hypertension